Pancreatic Cancer Screening in a Population at High Risk

Launched by MASARYK MEMORIAL CANCER INSTITUTE · Mar 19, 2024

Keywords

ClinConnect Summary

The SCREPAN trial is focused on finding ways to screen for pancreatic cancer in people who are at high risk of developing the disease. Pancreatic cancer is often difficult to detect early because it usually does not show symptoms until it is very advanced. This study is particularly important in the Czech Republic, where the number of pancreatic cancer cases is rising. The trial aims to monitor individuals who have certain hereditary conditions or a family history of pancreatic cancer, which can increase their risk.

To be eligible for the study, participants must be at least 18 years old and willing to take part. There are specific criteria based on individual health conditions and family history. For example, people with chronic pancreatic diseases, certain hereditary syndromes, or a close family member who has had pancreatic cancer may qualify. Participants can expect regular check-ups and screenings to monitor their health. This trial not only aims to improve early detection of pancreatic cancer but also provides valuable information that could help others in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • willing to participate in the study
• • age 18+
• * arms specific criteria:
• A:
• • chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis
• • age 50+
• B1:
• • confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
• • familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member
• • confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack
• B2:
• • confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome /mutTP53/)
• • at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative)
• • age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first
• C:
• • positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context
• • age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members
• Exclusion Criteria:
• • Inability to undergo radical curative surgery for a pancreatic tumor.
• • Inability to undergo scheduled imaging examinations.
• • Incurable malignant cancer.